Publication details

Antikoaguační léčba v sekundární prevenci ischemické cévní mozkové příhody a trazitorní ischemické ataky kardioembolické etiologie

Authors

BEDNAŘÍK Josef TOMEK Aleš BAR Michal NEUMANN Jiří ŠAŇÁK Daniel LÍČENÍK Radim NEČAS Tomáš BÚŘILOVÁ Petra KLUGAROVÁ Jitka KLUGAR Miloslav

Year of publication 2019
MU Faculty or unit

Faculty of Medicine

Web https://kdp.uzis.cz/res/guideline/ischemicka-cevni-mozkova-prihoda-nebo-tranzitorni-ischemicka-ataka-kardioembolicke-etiologie-jejich-sekundarni-prevence-final.pdf
Description Ischemic strokes (iCMP) account for 88% of all strokes, in the Czech Republic the incidence of iCMP is currently 211 cases per 100 000 population per year and the prevalence is estimated at 240 000 cases. The most common type of ischemic stroke is cardioembolic stroke and its most common cause is non-valvular atrial fibrillation (AF) or atrial flutter. FS is the most common arrhythmia in the adult population. For primary and secondary prevention of iCMP in patients with FS, anticoagulant therapy with a vitamin K antagonist (warfarin) or direct oral anticoagulants (DOACs) factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) and factor IIa inhibitor (dabigatran) is indicated. The main objective of this clinical guideline is to provide recommendations for the care of adult patients with iCMP and TIA based on the best available evidence. Translated with www.DeepL.com/Translator (free version)

You are running an old browser version. We recommend updating your browser to its latest version.

More info